The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients
Abstract
Purpose: To report the results of a planned safety analysis from a phase III trial comparing capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil/leucovorin (FU/LV) as adjuvant therapy for stage III colon cancer. Patients and Methods: Patients with stage III colon carcinoma were randomly assigned to receive either XELOX (intravenous oxaliplatin plus oral capecitabine; 3-week cycle for eight cycles) or standard intravenous bolus FU/LV administered as the Mayo Clinic (Mayo; Rochester, MN) or Roswell Park (RP; Buffalo, NY) regimen for a similar length of time. A total of 1,886 patients were randomly assigned. Results: The safety population comprised 1,864 patients, of whom 938 received XELOX and 926 received FU/LV. Most treatment-related adverse events (AEs) occurred at similar rates in both treatment arms. However, patients receiving XELOX experienced less all-grade diarrhea, alopecia, and more neurosensory toxicity, vomiting, and hand-foot syndrome than those patients receiving FU/LV. Compared with Mayo, XELOX showed fewer grade 3/4 hematologic AE and more grade 3/4 gastrointestinal AE. Compared with RP, XELOX showed less grade 3/4 gastrointestinal AE and more grade 3/4 hematologic AE. As expected grade 3/4 neurosensory toxicity and grade 3 hand-foot syndrome were higher with XELOX. Treatment-related mortality within 28 days from the last study dose was 0.6% in the XELOX group and 0.6% in the FU/LV group. Conclusion: XELOX has a manageable tolerability profile in the adjuvant setting. Efficacy data will be available within the next 24 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Self-citationCapecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Self-citationO'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., & Wieand, H. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.246 · Cited by 585
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Self-citationCassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Self-citationCutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
Self-citationHaller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., & Mayer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5686 · Cited by 391
Self-citationScheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E. L., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg500 · Cited by 276
Self-citationWolmark, N., Wieand, S., Kuebler, J. P., Colangelo, L., & Smith, R. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba3500 · Cited by 176
Scheithauer, W., Kornek, G. V., Raderer, M., Schüll, B., Schmid, K., Kovats, E., Schneeweiss, B., Lang, F., Lenauer, A., & Depisch, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.016 · Cited by 174
Cited by
Bang, Y.-J., Kim, Y.-W., Yang, H.-K., Chung, H. C., Park, Y.-K., Lee, K. H., Lee, K.-W., Kim, Y. H., Noh, S.-I., Cho, J. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,705
Self-citationSchmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Self-citationAdjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0021 · Cited by 806
Haller, D. G., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Gilberg, F., Rittweger, K., & Schmoll, H.-J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.6297 · Cited by 784
Self-citationLabianca, R., Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Pessi, M. A., Prochilo, T., Quadri, A., Gatta, G., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.010 · Cited by 409
Self-citationHong, Y. S., Nam, B.-H., Kim, K.-P., Kim, J. E., Park, S. J., Park, Y. S., Park, J. O., Kim, S. Y., Kim, T.-Y., Kim, J. H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70377-8 · Cited by 383
Self-citationLabianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq168 · Cited by 340
Schmoll, H.-J., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Hoersch, S., Rittweger, K., & Haller, D. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9107 · Cited by 291
Self-citationS3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008
Schmiegel, W., Reinacher-Schick, A., Arnold, D., Graeven, U., Heinemann, V, Porschen, R., Riemann, J., Rödel, C., Sauer, R., Wieser, M., et al. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027726 · Cited by 274
Self-citationPotential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
Haller, D. G., Cassidy, J., Clarke, S. J., Cunningham, D., Van Cutsem, E., Hoff, P. M., Rothenberg, M. L., Saltz, L. B., Schmoll, H.-J., Allegra, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2090 · Cited by 252
Self-citationGastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation
Lee, C. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3751 · Cited by 224
Adjuvant chemotherapy in resected colon cancer: When, how and how long?
Gelibter, A. J., Caponnetto, S., Urbano, F., Emiliani, A., Scagnoli, S., Sirgiovanni, G., Napoli, V. M., & Cortesi, E. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.06.003 · Cited by 75
Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
Kim, S. T., Kim, S. Y., Lee, J., Yun, S. H., Kim, H. C., Lee, W. Y., Kim, T. W., Hong, Y. S., Lim, S.-B., Baek, J. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02962 · Cited by 21
Self-citation
Metadata
- Authors
- Schmoll, H.-J., Cartwright, T., Tabernero, J., Nowacki, M. P., Figer, A., Maroun, J., Price, T., Lim, R., Van Cutsem, E., Park, Y.-S., McKendrick, J., Topham, C., Soler-Gonzalez, G., de Braud, F., Hill, M., Sirzén, F., & Haller, D. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 102-109
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2069030010
- Cited by
- 298
- References
- 16
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.